 Cytomegalovirus CMV intravenous immunoglobulin prevention primary CMV infection disease marrow transplant Cytomegalovirus CMV -specific immunoglobulin IVIG randomized trial CMV-seronegative marrow transplant patients seropositive marrow donors prevention primary CMV infection first days transplant Patients mg/kg CMV IVIG days transplant day transplant first month weeks doses Patients weekly CMV cultures serologic studies clinical histologic evidence CMV disease Sixty patients evaluable group CMV excretion viremia treatment group incidence CMV disease CMV pneumonia CMV enteritis CMV syndrome fever leukopenia hepatitis different difference median time onset CMV infection disease median number hospital days survival groups